Efficacy and safety of laquinimod in multiple sclerosis: current status

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis

(2013) Valérie Jolivel et al.   BRAIN

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

(2012) Wolfgang Brück et al.   ACTA NEUROPATHOLOGICA

Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis

(2012) Elias Toubi et al.   JOURNAL OF NEUROIMMUNOLOGY

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

(2012) Rina Aharoni et al.   JOURNAL OF NEUROIMMUNOLOGY

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis

(2012) Francesca Ruffini et al.   Multiple Sclerosis Journal

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity

(2012) Ulf Schulze-Topphoff et al.   PLoS One

Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor

(2011) Jan Thöne et al.   AMERICAN JOURNAL OF PATHOLOGY

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

(2010) Christiane Wegner et al.   JOURNAL OF NEUROIMMUNOLOGY

Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: In-vitro high-throughput gene expression study

(2010) M. Gurevich et al.   JOURNAL OF NEUROIMMUNOLOGY

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

(2010) G. Comi et al.   Multiple Sclerosis Journal

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET